Job Opportunities API

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As a Director, Molecular Pathology, you will be a key member of a cross-functional Translational Sciences Team, reporting to the Senior Director and Head of Translational Sciences within Translational Research and will: Biomarker Strategy: Define and execute molecular and digital pathology-driven biomarker strategies. Integration of Advanced Modalities: Lead adoption of molecular pathology and spatial technologies (to support translational research and broader BDR needs. Digital & Computational Pathology: Drive implementation of whole-slide imaging, AI/ML-based image analysis, and integration of spatial biomarker analytics into decision-making. Data Interpretation & Reporting: Provide expert interpretation of pathology data, ensuring robust correlation with clinical outcomes and mechanistic insights. Cross-functional Leadership: Collaborate with Translational Medicine, Bioinformatics, and Clinical Development colleagues to implement candidate biomarkers into Translational Biomarker plans for RAS(ON) inhibitors in alignment with overarching clinical development strategies. Responsibilities Scientific Leadership & Execution: Perform and interpret multiplex spatial biomarker datasets to inform Translational hypotheses and clinical strategies. Establish QC standards for data acquisition and analysis. Cross-Functional Collaboration: Partner within Research and Clinical teams to integrate spatial biomarker findings into translational plans. Collaborate with Systems Biology and Information Sciences teams to enable visualization tools External Partnership Management: Serve as primary scientific liaison to CROs for spatial biomarker workflows; review deliverables, troubleshoot issues, and drive continuous improvement. Capability Building: Document best practices and SOPs for spatial biomarker workflows; recommend platform upgrades and pilot evaluations. Required Skills, Experience & Education: 10+ years in digital pathology/spatial biology within pharma, biotech, or CRO settings. Scientific Expertise: Deep knowledge of spatial biology (e.g. spatial transcriptomics, Visium, Xenium, GeoMx, MerFish, etc.); ability to translate complex data into actionable insights Execution Excellence: Bias for action; delivers high-quality analyses under tight timelines Collaboration & Influence: Builds strong relationships across functions and with external partners; communicates clearly and persuasively. Innovation & Continuous Improvement: Identifies opportunities to enhance workflows and adopt emerging technologies. PhD/MD or equivalent in Cancer Biology, Translational Sciences, Pathology or related discipline. Preferred Skills: Hands-on experience with spatial pathology workloads. Familiarity with AI/ML-assisted pathology workflows and spatial statistics. Proven ability to manage CRO relationships and deliver time-sensitive biomarker analyses. #LI-Hybrid  #LI-LN1 The base pay salary range for this full-time position for candidates working onsite at our headquarters in Redwood City, CA is listed below. T